See today’s investors signing the most cheques in European healthtech in 2023, according to Dealroom data
BII is a non-profit accelerator/incubator, backed by a €470m donation from the Novo Nordisk Foundation. It backs pre-seed and pre-investment startups, including disease diagnostics startup Rapidemic and cancer treatment platform Metsystem.
See today’s BioWorld MedTech
Metsystem receives injection of funds to validate cancer metastasis prognosis platform
MEDWATCH 22.3.2023
Entrepreneurs create prognosis service for hospitals: Will identify patients at high risk of metastases.
Newly founded Metsystem aims to make its prognosis service available in 2025 initially to hospitals in Denmark, but later abroad and to pharmaceutical companies as a test of their cancer treatment in the preclinical stage.
